טוען...

INSTIGO Trial: Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relapse of Triple Negative Breast Cancer

BACKGROUND: Triple negative breast cancer (TNBC) accounts for 10-20% of breast cancers but has no specific therapy. While TNBC may be more sensitive to chemotherapy than other types of breast cancer, it has a poor prognosis. Most TNBC relapses occur during the five years following treatment, however...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Front Oncol
Main Authors: Veyssière, Hugo, Lusho, Sejdi, Molnar, Ioana, Kossai, Myriam, Bernadach, Maureen, Abrial, Catherine, Bidet, Yannick, Radosevic-Robin, Nina, Durando, Xavier
פורמט: Artigo
שפה:Inglês
יצא לאור: Frontiers Media S.A. 2021
נושאים:
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC8268015/
https://ncbi.nlm.nih.gov/pubmed/34249690
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.653370
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!